“For far too long, children with pJIA or PsA have had limited treatment options,” said Seth D. , Given the heterogeneity of these diseases, additional treatment options are needed for these conditions.
#Simponi aria skin#
PsA in pediatric patients is one of the rarest subtypes of JIA and is characterized by both joint inflammation and skin lesions associated with psoriasis resembling adult PsA. The polyarticular form of JIA is most common and is characterized by inflammation in more than four joints and resembles adult rheumatoid arthritis (RA). Approximately 300,000 children suffer from some form of JIA in the United States. JIA is a group of disorders characterized by arthritis persisting for at least six weeks before the age of 16 years. “For more than 20 years, we at Janssen have been committed to researching anti-TNF biologic agents for immune-mediated diseases and are encouraged to expand treatment options for these patients.” “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population.
HORSHAM, PA, Septem– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S.
0 kommentar(er)
